Is Inhibrx Biosciences financially healthy?
Not really
Inhibrx Biosciences earns only -11.1 times its interest bill, which leaves little room.
The numbers behind it
Net debt / EBITDANet cash
Cash vs. debt$124M vs. $107M
Current ratio3.9×Short-term assets for each $1 of bills due within a year
Interest coverage-11.1×How many times operating profit covers the interest bill
How we decide
We measure debt in years of earnings (net debt / EBITDA): under 1 is very comfortable, 1 to 3 is manageable, above 3 is heavy. A company that earns less than 3 times its interest bill also counts as weak.
More questions about Inhibrx Biosciences
Data as of Nov 13, 2026.